Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of YYC506 FDC vs Co-administration
NCT04874129Phase 1Unknown
- Sponsor
- Yooyoung Pharmaceutical
- Start
- Jan 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atorvastatin and fenofibrate in dyslipidemia (2 arms), sponsored by Yooyoung Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve at 48 hours. Status: unknown.
02
Drugs
atorvastatinfenofibrate
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT04874129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04874129.